Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a Dual-Axis Model of Microbiome Modulation in Cancer Immunotherapy: Pathobiont Elimination and Functional Ecosystem Restoration.

Cellular and molecular bioengineering·2026
Same author

Improving immunotherapy in solid tumors using FMT.

Cell·2026
Same author

Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting.

Annual review of immunology·2025
Same author

Multiregional CT Features Improve Prediction of Immunotherapy Response in Advanced Melanoma.

medRxiv : the preprint server for health sciences·2025
Same author

Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy.

Cell·2025
Same author

Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma.

Journal for immunotherapy of cancer·2025

Related Experiment Video

Updated: May 12, 2026

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

Strategies to reverse melanoma-induced T-cell dysfunction.

Julien Fourcade1, Hassane M Zarour

  • 1Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

Clinics in Dermatology
|April 24, 2013
PubMed
Summary

Understanding why melanoma immune responses fail is key to developing effective cancer treatments. Targeting immune escape mechanisms can enhance T-cell responses and improve clinical outcomes for advanced melanoma patients.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Experiment Videos

Last Updated: May 12, 2026

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Advanced melanoma patients exhibit spontaneous immune responses to tumor antigens.
  • Understanding the failure of these immune responses is critical for effective treatment.
  • Melanoma employs various immune escape mechanisms that hinder tumor regression.

Purpose of the Study:

  • To elucidate the mechanisms of melanoma-induced immune escape.
  • To identify factors within the tumor microenvironment that suppress antitumor immunity.
  • To inform the development of novel therapies targeting these suppressive elements.

Main Methods:

  • Review and synthesis of existing research on melanoma immunology and immune escape.
  • Analysis of suppressive factors in the tumor microenvironment, including cytokines, suppressive cells, and immune checkpoints.
  • Identification of defects in antigen presentation and processing by melanoma cells.

Main Results:

  • Multiple melanoma immune escape mechanisms have been identified.
  • Key suppressive factors in the tumor microenvironment include TGF-β, IL-10, regulatory T cells, MDSCs, and immune checkpoints (CTLA-4, PD-1/PD-L1).
  • Defective antigen presentation and amino acid catabolizing enzymes (IDO, arginase) contribute to immune suppression.

Conclusions:

  • Targeting identified immune escape mechanisms and suppressive microenvironment factors is crucial.
  • Therapies aimed at enhancing tumor antigen-specific T-cell responses hold promise.
  • These strategies can potentially increase clinical benefits for patients with advanced melanoma.